In Brief: Genzyme Sepracoat
This article was originally published in The Gray Sheet
Genzyme Sepracoat: Bioresorbable anti-adhesion solution receives European Union CE mark for use in abdominal, pelvic, and thoracic surgical procedures, the firm announces Aug. 19. Genzyme plans a forth quarter launch of the device in Denmark, Germany, Italy, The Netherlands, Sweden, and the United Kingdom. A PMA for Sepracoat, submitted in January ("The Gray Sheet" Jan. 29, In Brief), is under expedited review at FDA...
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.